You are here

Mobilize for MedTech

Today’s medical technology companies are developing exciting and innovative life changing products.  While the industry is more innovative than ever before, it continues to run into barriers and other hurdles that hinder innovation. Regulatory and payment issues continue to lengthen the amount of time is takes to get a product into the hands of physicians and patients.

Mobilize for MedTech is AdvaMed’s grassroots campaign, working to ensure that patients have timely access to life-changing technologies.

Urge Congress to Repeal the Device Tax

Top Issue:

The medical device tax is an excise tax on the sale of medical technology that was enacted as part of the Affordable Care Act (ACA). Since its enactment, the tax has had a significant, negative impact on medical innovation, and has resulted in the loss or deferred creation of jobs, reduced R&D, and slowed capital expansion.

In July 2018, we expect that the House will vote on H.R. 184, the Protect Medical Innovation Act of 2017. This bill would permanently repeal the medical device excise tax. Permanently repealing the device tax will provide medical technology innovators with the long-term certainty necessary to support future job growth and sustainable, cutting-edge R&D that will ultimately lead to the next generation of breakthroughs in patient care and treatment. In these uncertain times, it is vital that Congress hears from you that action is needed NOW to ensure this onerous tax is not re-imposed on our industry and the patients we serve. 

Please ask your Members of Congress to vote YES on H.R. 184 and repeal the medical device tax.er policy outcome, effective planning for a sustainable future becomes much more difficult.

Take Action

Urge Congress to Support U.S. MedTech Access to Global Markets

Recent trade actions proposed by the Administration and the US Trade Representative (USTR) have the ability to affect the medtech industry as a whole. In August, the Administration launched an investigation into China's trade practices under Section 301 of the Trade Act of 1974. USTR concluded that China was conducting unfair and harmful acquisition of U.S. technology. In response to this finding, the Administration directed USTR to propose 25 percent additional tariffs on imports that have benefited by China's trade practices, including about $3 billion in medtech. 

 
Through collaboration with Congress and the Administration, we seek to maintain our status as a net exporting industry, and to improve patient access to medtech around the world. It is important that we take this time to contact our Members of Congress and urge them to weigh in as the Administration is currently considering tariffs that could impact our ability to compete abroad. Please use the link below to urge Congress to Support U.S. MedTech Access to Global Markets.

Take Action

Payment Reform

Medicare’s coverage and reimbursement process for new technologies lacks predictability and transparency, delaying patient access to innovative new technologies.  AdvaMed is working with Congress on two approaches to reforming the CMS coverage and reimbursement process. First, improving coverage and reimbursement for breakthrough products while addressing current issues with the New Technology Add-on Payment program.  Second, improving the LCD (local coverage determination) process through enhanced transparency, predictability, and accountability.  

Learn More

FDA

Having an efficient, predicatable, and transparent FDA is good for the medical device industry and for the patients we serve.  One tool for ensuring the FDA is well-functioning is the medical device user fee program, or MDUFA.  MDUFA gives FDA the authority to collect user fees from industry to support review activities.  In exchange, FDA commits to meaningful performance goals to improve the agency’s review process.  These goals and accompanying process improvements translate into more timely patient aaccess to life-changing medical technologies.  AdvaMed is please that Congress took steps to pass a five-year reauthorization of the MDUFA program in August 2017, and will be working with FDA as it implements the terms of the agreement.

Learn More

Ways to Get Involved

Facility Tours:

As an industry, it is important that we maintain visibility with Congressional members while they are back in their districts and states. Welcoming elected officials to visit your company and providing them with a tour of your facility, affords you the chance to highlight your company and the impact you make in their district. This also provides the opportunity to develop a relationship with your Member of Congress, opening channels of communication should you need to reach out to their office in the future. If you are interested in hosting a Member of Congress at your facility, please contact Angie Comte at acomte@advamed.org, and we will be happy to help facilitate that visit.

AdvaMed Stateside:

The AdvaMed Stateside program is aimed at getting local industry employees to engage with their Members of Congress by attending meetings at their Member’s district office. AdvaMed handles the meeting logistics, as well as provides background documents and talking points.  We held more than 10 Stateside meetings in 2016, and are continuing the program this year. If your company would like to participate in the Stateside program moving forward, please let us know by contacting Angie Comte at acomte@advamed.org.